282 related articles for article (PubMed ID: 8486501)
1. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.
Harpur ES; Worah D; Hals PA; Holtz E; Furuhama K; Nomura H
Invest Radiol; 1993 Mar; 28 Suppl 1():S28-43. PubMed ID: 8486501
[TBL] [Abstract][Full Text] [Related]
2. Gadodiamide injection. First human experience with the nonionic magnetic resonance imaging enhancement agent.
Van Wagoner M; Worah D
Invest Radiol; 1993 Mar; 28 Suppl 1():S44-8. PubMed ID: 8486503
[TBL] [Abstract][Full Text] [Related]
3. Comparison of cardiovascular changes after administration of gadodiamide injection and gadopentetate dimeglumine in dogs.
Bøkenes J; Hustvedt SO; Refsum H
Acad Radiol; 1997 Mar; 4(3):204-9. PubMed ID: 9084778
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats.
Tweedle MF; Wedeking P; Kumar K
Invest Radiol; 1995 Jun; 30(6):372-80. PubMed ID: 7490190
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular responses after ionic and nonionic magnetic resonance contrast media in rats with acute myocardial infarction.
Li HT; Saeed M; Wendland MF; Higgins CB
Invest Radiol; 1993 Jan; 28(1):11-9. PubMed ID: 8425847
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging.
Schuhmann-Giampieri G; Frenzel T; Schmitt-Willich H
Arzneimittelforschung; 1993 Aug; 43(8):927-31. PubMed ID: 8216456
[TBL] [Abstract][Full Text] [Related]
7. Use of the magnetic resonance contrast agent gadodiamide in the central nervous system. Results of a multicenter trial.
Sze G; Brant-Zawadzki M; McNamara MT; Haughton VM; Kumar AJ; Maravilla KR; Aisen AM; Dreisbach JN; Bradley WG; Weinreb JC
Invest Radiol; 1993 Mar; 28 Suppl 1():S49-55. PubMed ID: 8486504
[TBL] [Abstract][Full Text] [Related]
8. Gadolinium Retention, Brain T1 Hyperintensity, and Endogenous Metals: A Comparative Study of Macrocyclic Versus Linear Gadolinium Chelates in Renally Sensitized Rats.
Rasschaert M; Emerit A; Fretellier N; Factor C; Robert P; Idée JM; Corot C
Invest Radiol; 2018 Jun; 53(6):328-337. PubMed ID: 29329151
[TBL] [Abstract][Full Text] [Related]
9. Safety aspects and pharmacokinetics of inhaled aerosolized gadolinium.
Berthezène Y; Mühler A; Lang P; Shames DM; Clément O; Rosenau W; Kuwatsuru R; Brasch RC
J Magn Reson Imaging; 1993; 3(1):125-30. PubMed ID: 8428078
[TBL] [Abstract][Full Text] [Related]
10. In vivo stability and excretion of gadodiamide (GdDTPA-BMA), a hydrophilic gadolinium complex used as a contrast enhancing agent for magnetic resonance imaging.
Normann PT; Hals PA
Eur J Drug Metab Pharmacokinet; 1995; 20(4):307-13. PubMed ID: 8983938
[TBL] [Abstract][Full Text] [Related]
11. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
[TBL] [Abstract][Full Text] [Related]
12. Hemodynamic effects of gadodiamide injection and gadopentetate dimeglumine in anesthetized dogs.
Peters JL; Shaw DD
Acta Radiol; 1993 Sep; 34(5):510-6. PubMed ID: 8369191
[TBL] [Abstract][Full Text] [Related]
13. Does Age Interfere With Gadolinium Toxicity and Presence in Brain and Bone Tissues?: A Comparative Gadoterate Versus Gadodiamide Study in Juvenile and Adult Rats.
Fretellier N; Granottier A; Rasschaert M; Grindel AL; Baudimont F; Robert P; Idée JM; Corot C
Invest Radiol; 2019 Feb; 54(2):61-71. PubMed ID: 30394964
[TBL] [Abstract][Full Text] [Related]
14. Acute cardiotoxicity of gadolinium-based contrast media: findings in the isolated rat heart.
Akre BT; Dunkel JA; Hustvedt SO; Refsum H
Acad Radiol; 1997 Apr; 4(4):283-91. PubMed ID: 9110026
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Evaluation of Gadolinium Retention in Rat Brain After Single Injection of a Clinically Relevant Dose of Gadolinium-Based Contrast Agents.
Strzeminska I; Factor C; Robert P; Grindel AL; Comby PO; Szpunar J; Corot C; Lobinski R
Invest Radiol; 2020 Mar; 55(3):138-143. PubMed ID: 31917763
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study.
Heinrich MC; Kuhlmann MK; Kohlbacher S; Scheer M; Grgic A; Heckmann MB; Uder M
Radiology; 2007 Feb; 242(2):425-34. PubMed ID: 17179401
[TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance imaging contrast media in the subarachnoid space. A comparison between gadodiamide injection and gadopentetate dimeglumine in an experimental study in pigs.
Skalpe IO; Tang GJ
Invest Radiol; 1997 Mar; 32(3):140-8. PubMed ID: 9055126
[TBL] [Abstract][Full Text] [Related]
18. Acute hemodynamic effects of recently developed monomer and dimer magnetic resonance imaging contrast media: a comparative study.
Geschwind JF; Saeed M; Wendland MF; Szolar D; Derugin N; Higgins CB
Acad Radiol; 1996 Aug; 3(8):667-77. PubMed ID: 8796731
[TBL] [Abstract][Full Text] [Related]
19. Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure.
Fretellier N; Bouzian N; Parmentier N; Bruneval P; Jestin G; Factor C; Mandet C; Daubiné F; Massicot F; Laprévote O; Hollenbeck C; Port M; Idée JM; Corot C
Toxicol Sci; 2013 Jan; 131(1):259-70. PubMed ID: 22977165
[TBL] [Abstract][Full Text] [Related]
20. Quantification and Assessment of the Chemical Form of Residual Gadolinium in the Brain After Repeated Administration of Gadolinium-Based Contrast Agents: Comparative Study in Rats.
Frenzel T; Apte C; Jost G; Schöckel L; Lohrke J; Pietsch H
Invest Radiol; 2017 Jul; 52(7):396-404. PubMed ID: 28125438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
